A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05764954

Enrollment

Registered

2023-03-13

Start date

2023-08-04

Completion date

2027-08-01

Last updated

2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of Lung

Keywords

NOVOTTF-200T system, TTFields treatment, 22-387

Brief summary

The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.

Interventions

DEVICENovoTTF-200T System

The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

22 Years to No maximum

Healthy volunteers

Inclusion criteria

* The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study. * The participant is ≥22 years of age on the day of signing informed consent. * The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection. * The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy. * The participant with multiple nodules has one nodule that meets the criteria. * The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.

Exclusion criteria

* Patients receiving therapy for concurrent active malignancy * Patients with a history of cardiac arrhythmias and/or pacemaker use * Patients with lung nodules \<1cm * Patients with lung nodules that are pure ground glass opacities (GGOs) of any size * Patients with lung nodules that are \<50% solid of any size

Design outcomes

Primary

Measure	Time frame	Description
Adverse events, severity and frequency	1 year	based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPrasad Adusumilli, MD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026